CEP97: Key Protein in Blood Clots and Immune System (G79598)

Target Name: CEP97

NCBI ID: G79598

CEP97

CEP97: Key Protein in Blood Clots and Immune System

CEP97, also known as CEP97 variant 1, is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. Its primary function is to regulate the formation of blood clots, which can potentially lead to the formation of emboli (small particles that can block blood vessels) and cause blood clots to break down and form new clots.

Research has shown that CEP97 plays a crucial role in the formation of blood clots and their disruption. This is because it is a key player in the process of platelet aggregation, which is the formation of blood clots. Platelets are responsible for forming the thrombusthat is used to stop bleeding after an injury or surgery. During platelet aggregation, CEP97 helps to regulate the formation of new platelets and the breaking down of existing platelets, which are a key part of the blood clot.

In addition to its role in blood clot formation, CEP97 has also been shown to play a key role in the regulation of the immune system. This is because it is a receptor for several antigens, including bacteria, viruses, and fungi. When an antigen binds to CEP97, it can trigger an immune response, which is essential for protecting the body against infection and disease.

Furthermore, CEP97 has also been shown to play a role in the regulation of the cell cycle. This is because it is a transcription factor, which means that it can cause the DNA in a cell to be copied and transcribed into RNA. This process is essential for the development and maintenance of new cells, and it is a critical part of the cell cycle.

As a potential drug target, CEP97 is being studied for its ability to treat a variety of conditions, including blood clots, cancer, and neurological disorders. For example, research has shown that CEP97 can be used to treat deep-vein thrombosis (DVT) , which is a common condition that can cause swelling and pain in the legs and ankles. In addition, CEP97 has also been shown to be effective in treating certain types of cancer, including breast cancer and colorectal cancer.

Overall, CEP97 is a protein that plays a critical role in the regulation of blood clots and the immune system. As a potential drug target, it has the potential to treat a variety of conditions, including blood clots, cancer, and neurological disorders. Further research is needed to fully understand the role of CEP97 in these processes and to develop effective treatments.

Protein Name: Centrosomal Protein 97

Functions: Acts as a key negative regulator of ciliogenesis in collaboration with CCP110 by capping the mother centriole thereby preventing cilia formation (PubMed:17719545, PubMed:30375385). Required for recruitment of CCP110 to the centrosome (PubMed:17719545)

The "CEP97 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEP97 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets